Regulatory wins for AZ

Thursday 10 November 2022

United Kingdom

AstraZeneca Plc won 19 regulatory approvals for its portfolio of biopharmaceuticals in the four months to early November representing a step-change from the recent past. Approvals were evenly distributed across geographies and reflected the company’s global ambitions.

At the company’s third quarter press briefing on 10 November, Pascal Soriot, the chief executive, said AstraZeneca intends to spend a significant proportion of its revenue on R&D going forward as it has in the recent past.